94.15
2.56%
-2.47
시간 외 거래:
94.15
전일 마감가:
$96.62
열려 있는:
$96.78
하루 거래량:
653.05K
Relative Volume:
1.07
시가총액:
$5.90B
수익:
$434.41M
순이익/손실:
$-128.05M
주가수익비율:
-10.24
EPS:
-9.19
순현금흐름:
$-250.52M
1주 성능:
+6.16%
1개월 성능:
+8.88%
6개월 성능:
-8.33%
1년 성능:
+40.50%
Blueprint Medicines Corp Stock (BPMC) Company Profile
명칭
Blueprint Medicines Corp
전화
617-374-7580
주소
45 SIDNEY STREET, CAMBRIDGE, MA
BPMC을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
BPMC | 94.15 | 5.90B | 434.41M | -128.05M | -250.52M | -9.19 |
VRTX | 450.97 | 116.14B | 10.63B | -479.80M | -1.35B | 13.33 |
REGN | 738.00 | 81.10B | 13.85B | 4.65B | 3.32B | 35.06 |
ARGX | 605.92 | 36.23B | 1.86B | -40.29M | -1.28B | -4.16 |
ALNY | 244.89 | 31.59B | 2.09B | -332.26M | 16.06M | -4.14 |
BNTX | 113.13 | 27.12B | 3.30B | -501.07M | 1.03B | 11.54 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2023-10-27 | 업그레이드 | Oppenheimer | Perform → Outperform |
2023-08-21 | 재확인 | Needham | Buy |
2023-07-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
2023-06-05 | 다운그레이드 | SVB Securities | Market Perform → Underperform |
2023-01-03 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
2022-12-14 | 개시 | Needham | Buy |
2022-11-02 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2022-09-14 | 개시 | Berenberg | Buy |
2022-07-08 | 개시 | Oppenheimer | Outperform |
2022-06-27 | 개시 | Wells Fargo | Underweight |
2022-06-10 | 다운그레이드 | Citigroup | Neutral → Sell |
2022-06-01 | 업그레이드 | Jefferies | Hold → Buy |
2022-03-01 | 개시 | Citigroup | Neutral |
2022-02-17 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
2022-01-25 | 업그레이드 | Stifel | Hold → Buy |
2021-11-19 | 재개 | Morgan Stanley | Equal-Weight |
2021-09-30 | 재개 | Stifel | Hold |
2021-06-04 | 재개 | Robert W. Baird | Outperform |
2021-03-31 | 개시 | Credit Suisse | Neutral |
2020-12-03 | 개시 | Stifel | Hold |
2020-11-02 | 재확인 | H.C. Wainwright | Buy |
2020-11-02 | 다운그레이드 | Jefferies | Buy → Hold |
2020-10-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
2020-07-15 | 재확인 | H.C. Wainwright | Buy |
2020-05-05 | 개시 | Barclays | Equal Weight |
2020-03-17 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
2020-01-28 | 개시 | BMO Capital Markets | Market Perform |
2020-01-27 | 개시 | BMO Capital Markets | Market Perform |
2019-11-06 | 업그레이드 | Raymond James | Outperform → Strong Buy |
2019-10-22 | 개시 | JMP Securities | Mkt Outperform |
2019-10-03 | 개시 | H.C. Wainwright | Buy |
2019-09-12 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
2019-08-29 | 개시 | Piper Jaffray | Neutral |
2019-08-15 | 재개 | Raymond James | Mkt Perform |
2019-07-18 | 개시 | Deutsche Bank | Buy |
2019-05-23 | 재개 | Goldman | Buy |
2019-04-03 | 개시 | Morgan Stanley | Overweight |
2018-09-25 | 개시 | Leerink Partners | Outperform |
2017-12-11 | 재확인 | Goldman | Buy |
모두보기
Blueprint Medicines Corp 주식(BPMC)의 최신 뉴스
Blueprint Medicines director Coats sells $1.87 million in stock - Investing.com
Blueprint Medicines director Coats sells $1.87 million in stock By Investing.com - Investing.com UK
What is Zacks Research's Forecast for BPMC FY2024 Earnings? - MarketBeat
Segall Bryant & Hamill LLC Buys 14,668 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (LTS:0HOJ) Enterprise Value : $5,746.9 Mil (As of Nov. 20, 2024) - GuruFocus.com
Blueprint Medicines initiated with an Overweight at JPMorgan - MSN
Blueprint Medicines Co. (NASDAQ:BPMC) Stock Holdings Cut by Victory Capital Management Inc. - MarketBeat
JMP Securities Reaffirms Market Outperform Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines’ (BPMC) “Buy” Rating Reiterated at Needham & Company LLC - Defense World
Blueprint Medicines’ (BPMC) Buy Rating Reiterated at HC Wainwright - Defense World
Prime Capital Investment Advisors LLC Sells 6,476 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Sees Large Growth in Short Interest - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Given Buy Rating at Needham & Company LLC - MarketBeat
HC Wainwright Reiterates Buy Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
JP Morgan Initiates Coverage of Blueprint Medicines (BPMC) with Overweight Recommendation - MSN
Blood Cancer-Focused Blueprint Medicines Could Be 'Attractive Target For Partnerships': Analyst - Yahoo Finance
Key Takeaways From Blueprint Medicines Analyst Ratings - Benzinga
Blueprint Medicines (NASDAQ:BPMC) Now Covered by JPMorgan Chase & Co. - MarketBeat
Mastocytosis Treatment Market Forecasted for Major Expansion - openPR
Entropy Technologies LP Takes Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Co. (NASDAQ:BPMC) Holdings Raised by US Bancorp DE - MarketBeat
M&G Plc Makes New $9.10 Million Investment in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Stock Rating Upgraded by StockNews.com - MarketBeat
Blueprint Medicines' SWOT analysis: stock soars on Ayvakit success, pipeline potential - Investing.com
Blueprint Medicines discloses CDK2 inhibitors for cancer - BioWorld Online
Systemic Mastocytosis Treatment Market to Grow by USD 157.1 Million from 2024-2028, Driven by Aging Population and AI-Redefined Market LandscapeTechnavio - The Malaysian Reserve
Blueprint Medicines (NASDAQ:BPMC) Price Target Lowered to $151.00 at Wells Fargo & Company - Defense World
Q1 Earnings Forecast for BPMC Issued By HC Wainwright - MarketBeat
Emerald Advisers LLC Has $34.77 Million Position in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (NASDAQ:BPMC) Given “Buy” Rating at Needham & Company LLC - Defense World
Analysts Have Made A Financial Statement On Blueprint Medicines Corporation's (NASDAQ:BPMC) Third-Quarter Report - Yahoo Finance
Blueprint Medicines Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Q4 EPS Estimates for Blueprint Medicines Boosted by Wedbush - MarketBeat
Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales By Investing.com - Investing.com South Africa
Earnings call: Blueprint Medicines sees revenue soar with AYVAKIT sales - Investing.com
Blueprint Medicines Corporation (NASDAQ:BPMC) Q3 2024 Earnings Call Transcript - Insider Monkey
Blueprint Medicines stock target upgraded, buy rating on Ayvakit sales - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Receives "Buy" Rating from HC Wainwright - MarketBeat
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and Raised Guidance - GuruFocus.com
Blueprint Medicines Corp (BPMC) Q3 2024 Earnings Call Highlights: Record AYVAKIT Revenue and ... - Yahoo Finance
Blueprint Medicines Reports Strong Q3 2024 Results - TipRanks
Blueprint Medicines Corp earnings beat by $0.07, revenue topped estimates - Investing.com Australia
Blueprint Medicines shares buoyed by Ayvakit sales beat - Investing.com
Blueprint Medicines (NASDAQ:BPMC) Shares Gap UpHere's Why - MarketBeat
Needham & Company LLC Reaffirms "Buy" Rating for Blueprint Medicines (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Canada Finance
Blueprint Medicines: Q3 Earnings Snapshot - Marketscreener.com
Blueprint Medicines Reports Third Quarter 2024 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire
When Can We Expect A Profit From Blueprint Medicines Corporation (NASDAQ:BPMC)? - Simply Wall St
Assenagon Asset Management S.A. Lowers Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - MarketBeat
Blueprint Medicines Corp (BPMC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):